Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration in a rat model of embolic stroke

Circulation

Volumn 107, Issue 22, 2003, Pages 2837-2843

  Zhang, Li ^a   Zhang, Zheng Gang ^a   Zhang, Ruilan ^a   Morris, Daniel ^b   Lu, Mei ^b   Coller, Barry S ^c   Chopp, Michael ^a,d  

^a HENRY FORD HOSPITAL   (United States)

^b HENRY FORD HEALTH SCIENCES CENTER   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

^d OAKLAND UNIVERSITY   (United States)

Author keywords

Cerebral ischemia; Microcirculation; Plasminogen activators; Platelets

Indexed keywords

ABCIXIMAB; ALTEPLASE; COLLAGEN TYPE 4; FIBRINOGEN RECEPTOR ANTAGONIST; GELATINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MIXTURE; DRUG POTENTIATION; DRUG SAFETY; FIBRIN DEPOSITION; FIBRINOLYTIC THERAPY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; RAT; STROKE; THROMBOCYTE AGGREGATION; THROMBOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; BODY WEIGHT; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR CIRCULATION; CHEMOTHERAPY, ADJUVANT; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FIBRINOLYSIS; IMMUNOGLOBULIN FAB FRAGMENTS; INFARCTION, MIDDLE CEREBRAL ARTERY; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; INTRACRANIAL EMBOLISM; MALE; MICROCIRCULATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RATS; RATS, WISTAR; RECOVERY OF FUNCTION; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 0037709836     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000068374.57764.EB     Document Type: Article

References (31)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Lincoff AM, Topol EJ. Illusion of reperfusion: does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation. 1993;88:1361-1374.
3. Gold HK, Coller BS, Yasuda T. et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation. 1988;77:670-677.
4. Antman EM, Giugliano RP, Gibson CM, et al, for the TIMI 14 Investigators. Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis In Myocardial Infarction (TIMI) 14 trial. Circulation. 1999:99:2720-2732.
5. Dudek D, Bartus S. Zmudka K. et al. Assessment of myocardial reperfusion in patients with acute myocardial infarction treated with combination of fibrinolysis and IIb/IIIa platelet inhibitor [in Polish]. Przegl Lek. 2002;59:1-6.
6. Shuaib A, Yang Y, Nakada MT, et al. Glycoprotein IIb/IIIa antagonist, murine 7E3 F(ab′) 2, and tissue plasminogen activator in focal ischemia: evaluation of efficacy and risk of hemorrhage with combination therapy. J Cereb Blood Flow Metab. 2002;22:215-222.
7. Antman EM, Gibson CM, de Lemos JA, et al. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Eur Heart J. 2000;21:1944-1953.
8. Zhang ZG, Zhang L, Tsang W, et al. Dynamic platelet accumulation at the site of the occluded middle cerebral artery and in downstream microvessels is associated with loss of microvascular integrity after embolic middle cerebral artery occlusion. Brain Res. 2001;912:181-194.
9. Sawicki G, Salas E, Murat J. et al. Release of gelatinase A during platelet activation mediates aggregation. Nature. 1997;386:616-619.
10. Fernandez-Patron C, Martinez-Cuesta MA, Salas E, et al. Differential regulation of platelet aggregation by matrix metalloproteinase-9 and -2. Thromb Haemost. 1999:82:1730-1735.
11. Zhang RL, Chopp M, Zhang ZG, et al. A rat model of focal embolic cerebral ischemia. Brain Res. 1997;766:83-92.
12. 2, an effective antagonist of rat alphaIIbbeta3 and alphavbeta3 blocks in vivo thrombus formation and in vitro angiogenesis. Thromb Haemost. 2001;85:896-902.
13. Korninger C, Collen D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost. 1981;46:561-565.
14. Foellmer HG, Madri JA, Furthmayr H. Methods in laboratory investigation: monoclonal antibodies to type IV collagen: probes for the study of structure and function of basement membranes. Lab Invest. 1983;48:639-649.
15. Asahi M, Wang X, Mori T, et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci. 2001:21:7724-7732.
16. Green LM, Reade JL, Ware CF. Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines. J Immunol Methods. 1984;70:257-268.
17. Asahi M, Wang X, Mori T, et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci. 2001;21:7724-7732.
18. Chen J, Li Y, Wang L, et al. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke. 2001;32:1005-1011.
19. Hernandez TD, Schallert T. Seizures and recovery from experimental brain damage. Exp Neurol. 1988;102:318-324.
20. Zhang ZG, Bower L, Zhang RL, et al. Three-dimensional measurement of cerebral microvascular plasma perfusion, glial fibrillary acidic protein and microtubule associated protein-2 immunoreactivity after embolic stroke in rats: a double fluorescent labeled laser-scanning confocal microscopic study. Brain Res. 1999;844:55-66.
21. Coller BS, Folts JD, Smith SR, et al. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor: correlation with bleeding time, platelet aggregation and blockade of GPIIb/IIIa receptors. Circulation. 1989;80:1766-1774.
22. Zhang ZG, Chopp M, Goussev A, et al. Cerebral microvascular obstruction by fibrin is associated with upregulation of PAI-1 acutely after onset of focal embolic ischemia in rats. J Neurosci. 1999;19:10898-10907.
23. Puri RN, Colman RW. Reocclusion after thrombolytic therapy: strategies for inhibiting thrombin-induced platelet aggregation. Blood Coagul Fibrinolysis. 1993;4:465-478.
24. Reed GL, Matsueda GR, Haber E. Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating crosslinking of alpha 2-antiplasmin to fibrin. Thromb Haemost. 1992;68:315-320.
25. Braaten JV, Jerome WG, Hantgan RR. Uncoupling fibrin from integrin receptors hastens fibrinolysis at the platelet-fibrin interface. Blood. 1994; 83:982-993.
26. Stringer HA, van Swieten P, Heijnen HF, et al. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Arterioscler Thromb. 1994;14:1452.
27. Collet JP, Montalescot G, Lesty C, et al. Effects of abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention. Circulation. 2001; 103:2328-2331.
28. Levy DE, Brott TG, Haley EC Jr, et al. Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke. 1994;25:291-297.
29. Zhang ZG, Zhang L, Jiang Q, et al. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest. 2000;106:829-838.
30. Collen D. Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator? Ann Intern Med. 1990:112:529-538.
31. Sumii T, Lo EH. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke. 2002;33:831-836.